Logo.jpg
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 08:30 ET | Celsion CORP
        Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00...
Logo.jpg
Celsion Corporation Issues Letter to Stockholders
October 12, 2020 08:00 ET | Celsion CORP
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
provectus_logo.jpg
Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
September 21, 2020 12:45 ET | Provectus Biopharmaceuticals Inc.
Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
Logo.jpg
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
July 13, 2020 08:30 ET | Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Logo.jpg
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
June 25, 2020 08:00 ET | Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...
Logo.jpg
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
May 15, 2020 08:00 ET | Celsion CORP
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation...
Yiviva_Logo.jpg
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
April 06, 2020 07:00 ET | Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...
首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
April 06, 2020 07:00 ET | Yiviva
—— 利用整合系统生物学方法,由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海,美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司(Yiviva Inc.),在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌(HCC)的一线疗法IIb期研究,并于今年三月迎来了第一位受试者。 ...
Logo.jpg
Celsion Corporation Reports 2019 Financial Results and Provides Business Update
March 25, 2020 16:15 ET | Celsion CORP
Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J., March ...
Auransa new horizontal White BG no slogan.jpg
Auransa to Participate in BioCentury-BayHelix China Healthcare Summit 2019
November 12, 2019 08:05 ET | Auransa
PALO ALTO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical...